Jazz Pharmaceuticals (NASDAQ: JAZZ) recently announced that its phase 3 trial evaluating chemotherapy medication Zepzelca in second-line small-cell lung cancer failed to meet its primary endpoint of overall survival. Patients receiving Zepzelca, either alone or in combination with the chemotherapy medication irinotecan, did not live longer than patients receiving standard treatments.